Northbrook House


  • 2007

    £6M initial fundraising

  • 2008

    Successful phase II results in cat allergy

  • 2009

    3rd funding round (£15M)

  • 2010

    Positive phase II results in house dust mite & ragweed allergies

  • 2011

    £60M investment round

  • 2012

    Start of phase III in cat allergy

  • 2013

    Results from phase II cat allergy study show four-dose treatment maintains improvement 2 years later

  • 2014

    Raises £200M in successful IPO on the London Stock Exchange

  • 2015

    Raises £275M to fund acquisitions of Aerocrine and Prosonix


Circassia (CIR:LSE) is a specialty biopharmaceutical company focused on allergy and asthma. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities.  Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany and intends expanding this to further countries.  These products are also promoted in a number of other territories by the Company’s international network of partners.

Circassia’s broad-based development pipeline includes a range of treatments for allergy and asthma.  Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs).  Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies.  Circassia’s lead asthma product targets substitution of GSK’s Flixotide® pMDI, and was filed for regulatory approval in H2 2014.  The Company anticipates two further product filings by the end of H1 2016, targeting direct substitution of Serevent® pMDI and Seretide® pMDI.  Circassia is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Circassia was established in 2006.  The Company made good clinical progress, and in March 2014 undertook a successful initial public offering on the London Stock Exchange, raising over £200 million.  In June 2015, the Company completed a further share offer, raising £275 million to advance its strategy to commercialize its products independently and broaden its portfolio through the acquisitions of Aerocrine and Prosonix.

Interested? Looking to learn more? Contact us